Anemia in heart failure: Current evidence and challenges

Reviews in Cardiovascular Medicine

Volumn 8, Issue 2, 2007, Pages 78-86

  Tang, W H Wilson ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anemia; Erythropoiesis stimulating agents; Heart failure; Hemoglobin

Indexed keywords

AMLODIPINE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; FERRITIN; FERROUS GLUCONATE; FOLIC ACID; HEMOGLOBIN; IRON; METOPROLOL; MILRINONE; NITRIC OXIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SERASPENIDE;

ANEMIA; CANCER PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEMOGLOBIN DETERMINATION; HUMAN; IRON DEFICIENCY; KIDNEY FAILURE; NUTRITIONAL DEFICIENCY; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT INDICATION; TREATMENT OUTCOME;

ANEMIA; ERYTHROPOIETIN; HEART FAILURE, CONGESTIVE; HEMOGLOBINS; HUMANS; PROGNOSIS;

EID: 34447252589     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Volpe M, Tritto C, Testa U, et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol. 1994;74:468-473.
2. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-1744.
3. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38:955-962.
4. Maggioni AP, Opasich C, Anand I, et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail. 2005;11:91-98.
5. Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110:149-154.
6. Wagoner LE, Butler J, Oren R, et al. Anemia is common in patients with heart failure seen in speciality and community cardiology clinics: results from the STAMINA-HFP Registry (Study of Anemia in a Heart Failure Population) [abstract]. J Am Coll Cardiol. 2004;43:217A.
7. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation. 2003;107:223-225.
8. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J. 2005;149:391-401.
9. Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006;27:1440-1446.
10. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 2003;41:1933-1939.
11. Horwich TB, Fonarow GC, Hamilton MA, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780-1786.
12. Kalra PR, Collier T, Cowie MR, et al. Haemoglobin concentration and prognosis in new cases of heart failure. Lancet. 2003;362:211-212.
13. Kerzner R, Gage BF, Rich MW. Anemia does not predict mortality in elderly patients with heart failure. Am J Geriatr Cardiol. 2007;16:92-96.
14. Kosiborod M, Curtis JP, Wang Y, et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med. 2005;165:2237-2244.
15. Falk K, Swedberg K, Gaston-Johansson F, Ekman I. Fatigue and anaemia in patients with chronic heart failure. Eur J Heart Fail. 2006;8:744-749.
16. Baggish AL, van Kimmenade R, Bayes-Genis A, et al. Hemoglobin and N-terminal pro-brain natriuretic peptide: independent and synergistic predictors of mortality in patients with acute heart failure. Results from the International Collaborative of NT-proBNP (ICON) Study. Clin Chim Acta. 2007;381:145-150.
17. Bansal N, Tighiouart H, Weiner D, et al. Anemia as a risk factor for kidney function decline in individuals with heart failure. Am J Cardiol. 2007;99:1137-1142.
18. Palazzuoli A, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152:1096.e9-15.
19. O'Meara E, Clayton T, McEntegart MB, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006;113:986-994.
20. Felker GM, Shaw LK, Stough WG, O'Connor CM. Anemia in patients with heart failure and preserved systolic function. Am Heart J. 2006;151:457-462.
21. Grigorian Shamagian L, Varela Roman A, Garcia-Acuna JM, et al. Anaemia is associated with higher mortality among patients with heart failure with preserved systolic function. Heart. 2006;92:780-784.
22. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 2005;112:1121-1127.
23. Khan W, Deepak SM, Coppinger T, et al. Beta blocker treatment is associated with improvement in renal function and anaemia in patients with heart failure. Heart. 2006;92:1856-1857.
24. Kannel WB. Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur Heart J. 1987;8(suppl F):23-26.
25. Sandgren PE, Murray AM, Herzog CA, et al. Anemia and new-onset congestive heart failure in the general Medicare population. J Card Fail. 2005;11:99-105.
26. Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53-61.
27. Chatterjee B, Nydegger UE, Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur J Heart Fail. 2000;2:393-398.
28. Westenbrink BD, Visser FW, Voors AA, et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J. 2007;28:166-171.
29. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26:2232-2237.
30. van der Meer P, Lipsic E, Westenbrink BD, et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation. 2005;112:1743-1747.
31. Rady M, Jafry S, Rivers E, Alexander M. Characterization of systemic oxygen transport in end-stage chronic congestive heart failure. Am Heart J. 1994;128:774-781.
32. Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA. 1998;279:217-221.
33. Metivier F, Marchais SJ, Guerin AP, et al. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant. 2000;15(suppl 3):14-18.
34. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005;294:81-90.
35. Andreotti F, Coluzzi G, Lavorgna A, et al. Relation between nitric oxide metabolites and haemoglobin concentrations in patients with ischaemic heart disease. Heart. 2007;93:255-257.
36. Felker GM, Stough WG, Shaw LK, O'Connor CM. Anaemia and coronary artery disease severity in patients with heart failure. Eur J Heart Fail. 2006;8:54-57.
37. Hussein SJ, Jain R, Shlipak MG, et al. Chronic heart failure is not an independent cause of anemia [abstract]. J Card Fail. 2003;9:19.
38. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48:2485-2489.
39. Witte KK, Desilva R, Chattopadhyay S, et al. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J. 2004;147:924-930.
40. Formiga F, Chivite D, Castaner O, et al. Anemia in new-onset congestive heart failure inpatients admitted for acute decompensation. Eur J Intern Med. 2006;17:179-184.
41. Androne AS, Hryniewicz K, Hudaihed A, et al. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol. 2004;93:1254-1259.
42. Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(suppl 7):S21-S30.
43. Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol. 2003;92:625-628.
44. Sharma R, Francis DP, Pitt B, et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J. 2004;25:1021-1028.
45. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
46. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381-388.
47. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084.
48. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.
49. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1225-1227.
50. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, et al. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Card Fail. 2007;13:14-17.
51. Silverberg DS, Wexler D, Blum M, et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int. 2001;21(suppl 3):S236-S240.
52. Silverberg DS, Wexler D, Blum M, et al. Effects of treatment with epoetin beta on outcomes in patients with anaemia and chronic heart failure. Kidney Blood Press Res. 2005;28:41-47.
53. Mishra TK, Mishra SK, Mohanty NK, Rath PK. Prevalence, prognostic importance and therapeutic implications of anemia in heart failure. Indian Heart J. 2005;57:670-674.
54. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18:141-146.
55. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-299.
56. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2007;49:753-762.
57. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet. 2006;368:947-953.